IBD- a paradigm for personalised medicine?

Jack Satsangi completed undergraduate training at St Thomas’s Hospital Medical School in 1987, and subsequently trained in Oxford, where he initiated the IBD gene discovery programme under supervision of John Bell, Mark Lathrop and Derek Jewell in 1993, in the original Wellcome Trust Centre for Human Genetics. He was appointed as Professor of Gastroenterology at the University of Edinburgh in September 2000.   He combines clinical gastroenterology, in which his main focus is the management of inflammatory bowel disease, with a programme of academic activities – including basic, clinical and translational research. His main clinical interests include the efficacy and safety of biological agents, and management of childhood-onset disease in adulthood. 

Major active research interests include IBD genetics, epigenetics and biomarker discovery, and a series of clinical trials  -most notably in post-operative prophylaxis, stem cell transplantation, and severe colitis. He is a PI of the UKIBD Genetics Consortium, and founder member of the International IBD Genetics Consortium.